Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 25, 2007 Brian Lawler	Acorda at a Glance Acorda Therapeutics has given astute biotech investors quite a ride over the last 12 months following positive results for their lead drug, Fampridine-SR. That drug now takes another step towards FDA approval. Investors, take note.
The Motley Fool January 29, 2008 Brian Lawler	Acorda Rides the Wave Acorda Therapeutics announces positive clinical trial data on its lead multiple sclerosis drug.
The Motley Fool December 11, 2006 Brian Lawler	Acorda Calls for 2 More Trials It'll be awhile before the FDA makes its decision on the pharma's new MS drug and the stock price settles down.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool March 30, 2010 Brian Orelli	FDA Lags, Investors Flee Cephalon gets no love from the FDA. The agency failed to expand Cephalon's Nuvigil for the treatment of jet lag.
The Motley Fool June 3, 2008 Brian Orelli	Taking a Walk With a 10-Bagger Acorda Therapeutics gets it done with phase 3 trial data on a new MS drug.
BusinessWeek April 9, 2007 Gene G. Marcial	Acorda Tackles Multiple Sclerosis A Corda Therapeutics isn't your typical biotech.
The Motley Fool June 3, 2011 Brian Orelli	FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully.
The Motley Fool March 21, 2011 Brian Orelli	Let's See Some Data, Curis Curis investors seem to have shrugged off the multiple unknowns and embraced the potential for the company's skin cancer drug.
The Motley Fool January 25, 2010 Brian Orelli	No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday.
The Motley Fool January 3, 2011 Brian Orelli	Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.
The Motley Fool November 3, 2006 Brian Lawler	Acorda's Wild Ride Positive trials help propel the stock to seven times its yearly low. Investors in the pharmaceutical since the company's IPO have been richly rewarded for their patience this year.
The Motley Fool December 31, 2011 Brian Orelli	3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012.
The Motley Fool July 27, 2010 Jim Mueller	3 Stocks to Play Biotech Here are three promising ideas for this exciting area.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool April 5, 2010 Brian Orelli	Up 30%? What Are You People On? Fast-track designations aren't worth much more than the paper they're printed on.
The Motley Fool November 1, 2011 Brian Orelli	Not Such an Excellent Outcome With the FDA Exelixis gets knocked down for not getting an SPA.
The Motley Fool December 27, 2011 Brian Orelli	Exelixis 2011: Not What the Doctor Ordered A tale of an inability to get a Special Protocol Assessment from the FDA.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool September 8, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool July 29, 2011 Brian Orelli	2 Biotechs, 1 Promising Cancer Drug Perifosine on the home stretch.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool October 15, 2009 Robert Steyer	Little Discord on Acorda Drug FDA advisory panel overwhelmingly backs a drug to improve the walking ability of multiple sclerosis patients.
The Motley Fool December 29, 2006 Brian Lawler	Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide.
The Motley Fool May 18, 2009 Brian Orelli	Is There Life After 600% Returns? Just because a drug company gets a massive increase in the stock price after a positive clinical trial or an FDA approval, that doesn't mean all the growth is completely factored into the stock price.
The Motley Fool September 14, 2010 Luke Timmerman	Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug.
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
The Motley Fool August 27, 2010 Brian Orelli	Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen.
The Motley Fool March 3, 2011 Brian Orelli	3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year.
The Motley Fool April 29, 2011 Brian Orelli	Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya.
The Motley Fool July 31, 2007 Brian Orelli	GPC Takes a Pit Stop The biotech company pulls its New Drug Application for Satraplatin. There is something twisted about having to wait to get a drug to market because it's performing better than expected. Investors, take note.
The Motley Fool June 4, 2007 Brian Orelli	OXiGENE's Moving Ahead The drug maker reaches a deal with FDA on its lead compound. Investors, take note.
The Motley Fool February 26, 2007 Brian Lawler	Waiting on AtheroGenics The results might be positive for this pharma, but don't bet on it. Investors, take note.
The Motley Fool February 1, 2011 Brian Orelli	Orexigen Falls Short Its obesity drug fails in the final mile of the drug-development marathon.
The Motley Fool November 25, 2008 Brian Orelli	Genentech Exhales The biotech had everything to lose and almost nothing to gain with its recent clinical trial.
The Motley Fool May 31, 2011 Brian Orelli	5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals.
The Motley Fool March 10, 2010 Brian Orelli	Up 160% With Room to Run You've got to love biotech and InterMune.
The Motley Fool September 7, 2010 Luke Timmerman	Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too.
The Motley Fool April 7, 2011 Brian Orelli	Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market.
The Motley Fool August 18, 2011 Brian Orelli	Running the Correct Trial Isn't Enough MELA Sciences' stock is up on claim that their trial meets FDA guidance, but they still need to prove that the device actually works.
The Motley Fool March 28, 2011 Brian Orelli	Investors Jump for Yervoy! The Food and Drug Administration approval of Bristol-Myers Squibb's Yervoy came with some surprising labeling news.
The Motley Fool October 6, 2011 Brian Orelli	Data Published; Back to Waiting Phase 2 data for Aeterna Zentaris and Keryx's perifosine was published, but it's the phase 3 that's important.
The Motley Fool March 11, 2010 Jim Mueller	Is Medivation a Buy? What is the thinking with regards to Medivation today? It already got a big haircut last week. Is it worth investing in at these lower prices?
The Motley Fool April 17, 2007 Brian Lawler	Neurochem Must Wait The FDA delays a regulatory decision on Neurochem's lead compound. Investors, take note.
The Motley Fool March 16, 2011 Brian Orelli	Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial.
The Motley Fool January 7, 2011 Brian Orelli	A Biotech Roller Coaster Lexicon is back on the upswing.
The Motley Fool April 8, 2011 Brian Orelli	A Shutdown of Binary Events? A government shutdown will likely stop FDA approvals.
The Motley Fool January 28, 2011 Brian Orelli	Value Investing, Biotech Style Biotech investors should regard every binary event as a varying degree of confidence in a positive or negative result.
The Motley Fool October 12, 2010 Brian Orelli	Clinical Trial Positive! Shares Just Barely A story about expectations. Seattle Genetics is two for two in recent weeks.